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Differentially regulated microRNA (miRNA) are associated with hepatic fibrosis;
however, their potential usefulness for blocking hepatic fibrosis has not been
exploited fully. We examined the expression of miRNA in the liver of a transgenic
mouse model in which platelet-derived growth factor C (PDGF-C) is overex-
pressed (Pdgf-c Tg), resulting in hepatic fibrosis and steatosis and the eventual
development of hepatocellular carcinoma (HCC). Robust induction of miR-214 cor-
related with fibrogenesis in the liver of Pdgf-c Tg mice, atherogenic high-fat diet-
induced NASH mice, and patients with chronic hepatitis B or C. Pdgf-c Tg mice
were injected with locked nucleic acid (LNA)-antimiR-214 via the tail vein using
Invivofectamine 2.0 and the degree of hepatic fibrosis and tumor incidence
were evaluated. Pdgf-c Tg mice treated with LNA-antimiR-214 showed a marked
reduction in fibrosis and tumor incidence compared with saline or LNA-miR-con-
trol-injected control mice. In vitro, LNA-antimiR-214 significantly ameliorated
TGF-b1-induced pro-fibrotic gene expression in Lx-2 cells. MiR-214 targets a nega-
tive regulator of EGFR signaling, Mig-6. Mimic-miR-214 decreased the expression of
Mig-6 and increased the levels of EGF-mediated p-EGFR (Y1173 and Y845) and
p-Met (Tyr1234 ⁄ 1235) in Huh-7 cells. Conversely, LNA-antimiR-214 repressed the
expression of these genes. In conclusion, miR-214 appears to participate in the
development of hepatic fibrosis by modulating the EGFR and TGF-b signaling path-
ways. LNA-antimiR-214 is a potential therapy for the prevention of hepatic fibrosis.
H epatic fibrosis develops in the setting of chronic inflam-mation such as in chronic hepatitis B or C, alcoholic liver
disease, non-alcoholic steatohepatitis and autoimmune hepati-
tis. The progression of hepatic fibrosis is clinically associated
with liver cell dysfunction and portal hypertension, and fre-
quently with hepatocellular carcinoma (HCC).(1)
Hepatic fibrosis is initiated by the activation of stellate cells,
which are stimulated by pro-fibrotic cytokines such as trans-
forming growth factor (TGF)-b and platelet-derived growth
factor C (PDGF-C) and various external stimuli such as oxida-
tive stress. The overexpression of PDGF-C in the liver of a
recently developed transgenic mouse model (Pdgf-c Tg)
resulted in the progression of hepatic fibrosis and steatosis and
the development of HCC.(2) This mouse model showed the
close association between hepatic fibrosis and the occurrence
of HCC, and also suggested the possibility that inhibition of
hepatic fibrosis could be an attractive therapy to reduce the
incidence of HCC. Recently, we reported that the acyclic reti-
noid peretinoin prevented hepatic fibrosis and reduced the
development of HCC by targeting PDGF signaling in Pdgf-c
Tg mice.(3)
MicroRNA (miRNA) are small, endogenous, single-stranded,
non-coding RNA that regulate gene expression and play an
important role in various biological processes, including organ
development and differentiation, cell death, and proliferation,
as well as in various diseases including cancer.(4)
In the progression of hepatic fibrosis, several miRNA such
as miR-34a, miR-155, miR-199a ⁄b and miR-214 are upregu-
lated, while miR-29, miR-150 and miR-194 are downregu-
lated.(5) However, the functional relevance of these miRNA in
hepatic fibrosis has not been assessed fully in an in vivo
model. In the present study, using Pdgf-c Tg mice, we evalu-
ated the function and potential usefulness of miR-214 for
improving hepatic fibrosis and preventing the development of
HCC.
Materials and Methods
Detailed material and methods are described in the Data S1.
Clinical samples. Liver tissue samples were obtained
from patients with chronic hepatitis C or B as previously
described.(6,7) Normal controls were histologically normal tis-
sues and were obtained from patients who underwent partial
hepatectomy for metastatic liver tumors as previously
described.(6,7) Informed consent was obtained from all patients
and ethics approval for the study was obtained from the ethics
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committee for human genome ⁄gene analysis research at Kana-
zawa University Graduate School of Medical Science.
Mouse studies. The generation and characterization of Pdgf-
c Tg mice have been described previously.(2,3) Wild-type (WT)
and Pdgf-c Tg mice on a C57BL ⁄6J background were main-
tained in a pathogen-free animal facility under a standard
12:12 h light:dark cycle. To analyze the development of liver
fibrosis, 9-week-old male Pdgf-c Tg mice were injected with
saline, locked nucleic acid (LNA)-antimiR-control (scramble)
or LNA-antimiR-214 (Exiqon, Skelstedet, Denmark) containing
Invivofectamine 2.0 (Invitrogen, Carlsbad, CA, USA) twice
(with an interval of 1 week) via the tail vein. At 3 days after
the second injection, the mice were killed for analysis (n = 5
for each group).
To analyze tumorigenesis in the liver, 32-week-old male
Pdgf-c Tg mice were injected with LNA-antimiR-214, LNA-
antimiR-control or saline via the tail vein for a total of six
injections (50 lg each) with an interval of 3 weeks using
Invivofectamine 2.0 (20 mg ⁄ 200 lL). The mice were killed
1 week after the final injection. The incidence of hepatic
tumors, maximum tumor size and liver weight were evaluated
(n = 6 for each group). All animal experiments were carried
out in accordance with the Guidelines for the Care and Use of
Laboratory Animals at the Takara-Machi Campus of Kanazawa
University, Japan.
Micro RNA expression in the liver of Pdgf-c Tg mice. Micro
RNA expression levels in the liver of Pdgf-c Tg mice were
evaluated using TaqMan Array Rodent MicroRNA A Cards
v2.0 containing 384 miRNA assays (Applied Biosystems,
Carlsbad, CA, USA). Total RNA containing miRNA was iso-
lated from the liver tissues of WT and Pdgf-c Tg mice at 20
and 48 weeks of age (each n = 4) according to the protocol of
the mirVana miRNA Isolation Kit (Invitrogen). cDNA was
prepared by reverse transcription using 10 ng of each isolated
total RNA and 3 lL of each reverse transcription primer with
specific loop structures. Reverse transcription was performed
using the TaqMan MicroRNA Reverse Transcription Kit (Ap-
plied Biosystems) according to the manufacturer’s protocol.
Then, a mixture of 6.67 lL nuclease-free water, 10 lL Taq-
Man 29 Universal PCR Master Mix (No AmpErase UNG;
Applied Biosystems) and 2 lL TaqMan MicroRNA Assay
Mix, which was included in the kit, was prepared for each
sample in a 384-well plate; 1.33 lL of the reverse transcrip-
tion product was added to the mixture, and the amplification
reaction was performed on an ABI PRISM 7900HT (Applied
Biosystems). Relative expression levels were calculated after
normalization to RNU44.
Cell culture. Human embryonic kidney (HEK) 293AD,
immortalized hepatocytes (THTL-5b and TTNT),(8,9) human
hepatocellular carcinoma (HCC) cell lines (Huh-7, Huh-1,
HepG2, Hep3B, HLE and HLF) and human Lx-2 stellate cells
(kindly provided by Dr Scott Friedman, Mount Sinai School of
Medicine, New York, NY, USA) were maintained in DMEM
(Gibco, Grand Island, NY, USA) supplemented with 10% FBS
(Gibco), 1% L-glutamine (Gibco) and 1% penicillin ⁄ strepto-
mycin (Gibco) in a humidified atmosphere of 5% CO2 at 37°C.
Cultured cells in 12-well plates were grown to 70% confluence
and transfected with LNA-antimiR (10 nM; Exiqon), mimic
miRNA (50 nM; Invitrogen) and anti-mitogen-inducible gene 6
(Mig-6) siRNA (40 nM; Invitrogen) using Lipofectamine
RNAiMAX according to the manufacturer’s instructions. Trans-
fected cells were serum-depleted for 9 h and then treated with
3 ng ⁄mL recombinant human transforming growth factor
(TGF)-b1 (Merck KGaA, Darmstadt, Germany) for 24 h.
Results
Upregulated micro RNA in the progression of hepatic fibrosis
in Pdgf-c Tg mice. To determine whether specific miRNA were
correlated with PDGF-C-induced liver fibrosis, we analyzed
miRNA expression in whole liver from Pdgf-c Tg and non-
transgenic WT mice at 20 and 48 weeks of age using TaqMan
quantitative real-time detection-PCR (RTD-PCR). Out of the
381 miRNA tested, 17 were upregulated and 16 were down-
regulated (P < 0.05). Thirteen representative miRNA are
shown in Table 1 (P < 0.005). MiR-214 was the most signifi-
cantly upregulated; therefore, we focused on miR-214 for fur-
ther study. We confirmed that miR-214 was also upregulated
with the progression of hepatic fibrosis in patients with chronic
hepatitis C or B (Fig. S1a).(10) We also confirmed that miR-
214 was upregulated in an atherogenic high-fat diet
(Ath + HF) mouse model that induces oxidative stress and
steatohepatitis with cellular ballooning and fibrosis (Fig. S1b,
c).(11)
To explore which cell type expresses miR-214, we evaluated
its expression in the following cell lines: two human immor-
talized hepatocyte cell lines (THTL-5b and TTNT), four
human HCC cell lines (Huh-7, HepG2, HLE and HLF) and a
human stellate cell-derived cell line (Lx-2; Fig. 1a). The rela-
tive expression of miR-214 was high in two HCC cell lines
(HLE and HLF) and stellate cells (Lx-2). In murine cells, the
expression of miR-214 in a mouse embryo-derived fibroblast
cell line (NIH3T3) was significantly higher than in mouse pri-
mary hepatocytes (Fig. 1b, left). These results suggested that
miR-214 was mainly expressed in mesenchymal cells, but only
expressed at a low level in parenchymal hepatocytes. The
expression of miR-214 in the liver of Pdgf-c Tg mice
increased by threefold to fourfold compared with WT mice
(Table 1 and Fig. 1b middle). Interestingly, however, in situ
hybridization analysis demonstrated the increased expression
of miR-214 in hepatocytes (black arrows) as well as mes-
enchymal cells (white arrows) from Pdgf-c Tg mice (Fig. 1b,
right). In vitro, TGF-b1 (3 ng ⁄mL) significantly induced the
expression of miR-214 in Lx-2 cells, which was confirmed by
Table 1. Upregulated micro RNA in liver of PDGF-C Tg mice
compared with wild-type (WT) mice at 20 and 48 weeks
Number miRNA
PDGF-C Tg ⁄ WT
(20 weeks)











1 mmu-miR-214 8.39E-05 4.17 8.55E-05 3.70
2 mmu-miR-195 2.04E-04 2.94 2.62E-04 2.94
3 mmu-miR-497 2.78E-04 3.03 4.84E-04 3.33
4 mmu-miR-146b 3.47E-04 3.45 7.06E-03 3.45
5 mmu-miR-34a 5.36E-04 2.86 5.65E-04 2.70
6 mmu-miR-132 8.28E-04 2.63 1.65E-04 3.45
7 mmu-miR-199a-3 1.10E-03 2.56 1.33E-03 1.92
8 mmu-miR-155 2.65E-03 3.57 1.06E-04 2.86
9 mmu-miR-223 3.48E-03 4.35 1.53E-04 3.03
Downregulated
1 mmu-miR-486 1.76E-03 0.45 1.53E-04 0.36
2 mmu-miR-192 4.33E-03 0.52 4.19E-03 0.57
3 mmu-miR-122 4.40E-03 0.61 2.83E-02 0.65
4 mmu-miR-451 4.85E-03 0.39 1.46E-03 0.37
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RTD-PCR and in situ hybridization (Fig. 1c); however, the
same concentration of TGF-b1 did not induce miR-214
expression in Huh-7 cells (Fig. 1d). Therefore, we examined
whether miR-214 was transferred through exosomes from Lx-
2 cells to Huh-7 cells. The amount of miR-214 in exosomes
was 10-fold higher in cultured medium from Lx-2 cells than
from Huh-7 cells (Fig. S2a). The expression of miR-214 in
Huh-7 cells significantly increased by approximately threefold
by co-culture with Lx-2 cells and it was increased further by
co-culture with TGF-b1-stimulated Lx-2 cells (Fig. S2a).
When culture medium from Lx-2 cells or purified exosomes
from the culture medium of Lx-2 cells were added to the cul-
ture medium of Huh-7 cells, intracellular miR-214 levels in
Huh-7 cells were significantly upregulated, and they were
upregulated further by the addition of TGF-b1 (Fig. 1d).
These results indicated that exosomes containing miR-214
were released from Lx-2 cells and taken up by Huh-7 cells.
Interestingly, the expression of vimentin, cyclin D1 and alpha-
fetoprotein (AFP) was slightly but significantly increased in
Huh-7 cells by co-culture with Lx-2 cells, Moreover, Huh-7
cells formed a number of spheroids when co-cultured with
Lx-2 cells (Fig. S2b,c). These data implied that Huh-7 cells
acquired a more malignant tumor cell phenotype by co-culture
with Lx-2 cells. Therefore, it could be speculated that the
increased levels of miR-214 in the hepatocytes of Pdgf-c Tg
mice might be derived from surrounding stellate cells or
fibroblasts and increased miR-214 levels might play a role in
the transformation of hepatocytes.
We isolated hepatic stellate cells (HSC) from normal mouse
liver and evaluated the expression of miR-214 in HSC
(Fig. 1e). The expression of miR-214 was significantly upregu-
lated during the progression of trans-differentiation from HSC
to myofibroblast-like cells (Fig. 1f). Together with this trans-
differentiation, the expression of a-smooth muscle actin




Fig. 1. Regulation of miR-214 expression in hepatocytes and hepatic stellate cells. (a) The expression levels of miR-214 in different cell lines
(n = 6). (b) The expression levels of miR-214 in mouse primary hepatocytes (MPH) and NIH3T3 cells (left panel). The expression levels of miR-214
in the liver of non-transgenic wild-type (WT) and Pdgf-c Tg mice (middle; n = 6). In situ hybridization of miR-214 in the liver of WT and Pdgf-c
Tg mice (right panel; black arrows indicate hepatocytes and white arrows indicate mesenchymal cells). (c) Time course of miR-214 levels in Lx-2
cells following stimulation with transforming growth factor (TGF)-b1 (3 ng ⁄ mL; left; n = 6). In situ hybridization showing the intracellular accu-
mulation of miR-214 in Lx-2 cells following TGF-b1 treatment (24 h; right). (d) Intracellular miR-214 expression in Huh-7 cells by various factors.
Huh-7 cells were stimulated with TGF-b1 (3 ng ⁄ mL), medium (of Lx-2 cells) and exosomes (derived from the medium of Lx-2 cells). After 24 h
stimulation, intracellular miR-214 expression was evaluated (n = 6; left). In situ hybridization of the intracellular accumulation of miR-214 in
Huh-7 cells exposed to the medium of Lx-2 cells (right). (e) Morphology of freshly isolated quiescent hepatic stellate cells (day 3) and activated
myofibroblast-like cells (day 12). (f) The expression of miR-214, a-SMA and TIMP2 was upregulated during spontaneous trans-differentiation of
stellate cells to myofibroblast-like cells. The TaqMan assay was performed in duplicate and repeated three times. Values are means  SD.
*P < 0.05, **P < 0.01, ***P < 0.001. In situ hybridization was repeated three times.
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Functional relevance of miR-214 in fibrogenesis in vitro. To
examine the functional relevance of miR-214 in fibrogenesis,
we knocked down the expression of miR-214 using LNA-an-
timiR-214 in Lx-2 and HLF cells (Fig. 2a,b). The expression
of collagen 1a2, collagen 4a1, fibronectin 1, PDGF receptor
b (PDGFRb) and N-cadherin was significantly repressed fol-
lowing the repression of miR-214, which was confirmed by
TaqMan RTD-PCR and western blotting. Furthermore, LNA-
antimiR-214 significantly ameliorated the TGF-b1-induced
expression of collagen 1a2, collagen 4a1, phosphorylated
(p)-mothers against DPP homolog (Smad) 3C and p-Smad3L
in Lx-2 cells. These findings were analyzed by RTD-PCR
(Fig. 2c), immunofluorescence staining (Fig. 2d) and western
blotting (Fig. 2e).
Gene expression profiling in Lx-2 cells in which miR-214
was knocked down with LNA-antimiR-214 was obtained using
an Affymetrix GeneChip. A total of 1437 genes were down-
regulated and 880 genes were upregulated (P < 0.005). The
changes in the levels of representative genes are shown in
Table S1. The expression of collagen 1a2, collagen 4a1,
EGFR, endothelin, a-SMA, TGF-b2, Smad3 and PDGFRb
was significantly downregulated by repression of miR-214.
Pathway analysis of these genes by functional enrichment anal-
ysis using MetaCore (Thomson Reuters, New York, NY, USA)
showed that neurogenesis, cytoskeleton, ErbB, cell adhesion
and epithelial–mesenchymal transition (EMT) signaling were
downregulated, while transcription and translation signaling
were activated (Fig. S2). These results showed the functional
relevance of miR-214 in fibrogenesis.
Repression of miR-214 with locked nucleic acid-antimiR-214
ameliorates hepatic fibrosis in Pdgf-c Tg mice. We evaluated the
effect of repressing miR-214 in vivo using Pdgf-c Tg mice.
Pdgf-c Tg mice at 9 weeks of age were injected with LNA-an-
timiR-214 via the tail vein twice (50 lg each) at an interval of
7 days by using Invivofectamine 2.0 (Fig. 3a).(12) Three days
after the second injection, the mice were killed for evaluation.
In situ hybridization of miR-214 in the liver of Pdgf-c Tg
mice showed a marked decrease in the expression of miR-
214 by LNA-antimiR-214 (Fig. 3b). Analysis of the gross






Fig. 2. Functional roles of miR-214 expression in hepatocytes and hepatic stellate cells. (a, b) Depletion of miR-214 in Lx-2 cells (a) and HLF cells
(b) decreased the expression of pro-fibrotic and epithelial–mesenchymal transition-related genes. Gene and protein expression was examined by
TaqMan real-time detection-PCR (RTD-PCR; left) or western blotting (right), respectively (n = 6). (c) Locked nucleic acid (LNA)-antimiR-214 amelio-
rated the TGF-b1-induced expression of collagen 1a2 and 4a1 in Lx-2 cells in a dose-dependent manner (TaqMan RTD-PCR; n = 6). (d) Immunoflu-
orescence staining of collagen 1 and pSmad3L in Lx-2 cells. TGF-b1 (3 ng ⁄ mL) stimulation for 24 h increased the expression of collagen 1 and
pSmad3L, while transfection of LNA-antimiR-214 canceled the increase in the expression of these genes. (e) Western blotting of p-Smad3 and p-
Smad3L in Lx-2 cells in the same experiment. The TaqMan assay was performed in duplicate and repeated three times. Values are means  SD.
*P < 0.05, **P < 0.01, ***P < 0.001. Western blotting and immunofluorescence staining were repeated three times.
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LNA-antimiR-214 showed a smooth surface of the liver
compared with control liver injected with saline or LNA-an-
timiR-control (scramble; Fig. 3c). Azan staining of fibrotic
tissues and immunohistochemical (IHC) staining of collagen
1 and desmin showed a significant improvement of the area
of fibrosis in the liver of Pdgf-c Tg mice injected with LNA-
antimiR-214 compared with saline or LNA-antimiR-control
(Fig. 3c).
These findings were also confirmed by TaqMan RTD-PCR
and western blotting (Fig. 4a). The upregulation of miR-214
was efficiently repressed by LNA-antimiR-214, while the
expression of collagen 1a2, collagen 4a1, TGF-b1, a-SMA and
TIMP2 was significantly repressed in the liver of Pdgf-c Tg
mice injected with LNA-antimiR-214 compared with mice
injected with saline or LNA-antimiR-control. Conversely, the
expression of matrix metallopeptidase 2 (MMP2) and MMP9
was significantly upregulated by LNA-antimiR-214. Correlated
with these results, western blotting analysis showed that the
increased levels of a-SMA and the phosphorylated forms of
extracellular signal-regulated kinase (ERK) 1 ⁄2 and V-Akt
murine thymoma viral oncogene homolog (AKT; p-ERK1 ⁄2
and p-AKT) were decreased in the liver of Pdgf-c Tg mice fol-
lowing injection with LNA-antimiR-214 (Fig. 4b). Conversely,
p-S6K levels were decreased in the liver of Pdgf-c Tg mice
and were recovered by injection with LNA-antimiR-214.
Repression of miR-214 with locked nucleic acid-antimiR-214
reduces tumor incidence in Pdgf-c Tg mice. We evaluated
whether repression of miR-214 with LNA-antimiR-214 could
reduce tumor incidence in Pdgf-c Tg mice. Pdgf-c Tg mice




Fig. 3. In vivo evaluation of hepatic fibrosis in
Pdgf-c Tg mice injected with locked nucleic acid
(LNA)-antimiR-214. (a) Experimental design: Pdgf-c
Tg mice at 9 weeks of age were injected with
saline, LNA-antimiR-control or LNA-antimiR-214 via
the tail vein twice (50 lg each; n = 5). Three days
after the second injection, the mice were killed for
evaluation. (b) In situ hybridization of miR-214 in
wild-type (WT) and Pdgf-c Tg liver injected with
LNA-antimiR-control or LNA-antimiR-214. (c)
Macroscopic findings of WT and Pdgf-c Tg liver
injected with saline, LNA-antimiR-control or LNA-
antimiR-214 (upper). Azan staining (2nd) and
immunohistochemical staining of collagen 1 (3rd)
and desmin (bottom) at sacrifice are shown.
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tic foci were detected in all Tg mice by 12 months.(2) Thirty-
two-week-old Pdgf-c Tg and WT mice were injected with
LNA-antimiR-214, LNA-antimiR-control or saline via the tail
vein for a total of six injections (50 lg each) at an interval of
3 weeks by using Invivofectamine 2.0 (Fig. 5a). At 1 week
after the final injection, the mice (each group = 6) were killed.
LNA-antimiR-214 substantially repressed the expression of
miR-214 in non-tumor and tumor lesions. Liver weight, tumor
size and tumor number were significantly reduced following
injection with LNA-antimiR-214 compared with saline or
LNA-antimiR-control (Fig. 5b,c). The fibrotic area in the liver
of control Pdgf-c Tg mice (saline group) increased from 13%
at 10 weeks to 28% at 47 weeks (Figs 4a, 5c and S3a).
Repeated injection with LNA-antimiR-214 reduced the fibrotic
area from 28% to 17%, indicating that LNA-antimiR-214 was
effective on advanced stage liver fibrosis. Moreover, serum
aspartate transaminase (AST) levels were significantly reduced,
while, conversely, the expression of albumin was significantly
increased following injection with LNA-antimiR-214 (Fig. 5c).
We did not observe obvious histological changes in the lung,
heart, kidney or spleen following repeated injection with LNA-
antimiR-214 for 15 weeks (data not shown).
Mir-214 increases EGFR signaling through repression of Mig-
6. To explore the underlying mechanisms by which miR-214
reduced liver growth in Pdgf-c Tg mice, we searched for target
genes of miR-214. We found that Mig-6, a negative regulator
of EGFR signaling,(13,14) contained a putative miR-214 binding
site at nucleotides (nt) 1288–1294 of its 30-untranslated region
(UTR; Fig. 6a). To examine whether the regulation of Mig-6
is mediated through its 30-UTR, we constructed a reporter plas-
mid, pmirGLO-Mig-6, consisting of a luciferase reporter gene
fused to a portion of the 30-UTR of Mig-6 (nt 748–1472) that
included the putative miR-214 binding site (Fig. 6a). Transfec-
tion of pmirGLO-Mig-6 and LNA-antimiR-214 into 293AD
cells significantly increased luciferase activity, while the trans-
fection of pmirGLO-Mig-6 and mimic-miR-214 significantly
decreased luciferase activity compared with the control (LNA-
antimiR-control or mimic-miR-control; Fig. 6b). In vivo, the
expression of Mig-6 was significantly decreased in the liver of
Pdgf-c Tg mice injected with saline or LNA-antimiR-control,
while it recovered following injection with LNA-antimiR-214
(Fig. 6c). Western blotting analysis showed that the expression
of EGFR and the levels of p-EGFR (Y1173), p-MET
(Tyr1234 ⁄1235) and p-AKT (Ser473) were decreased in the
liver of Pdgf-c Tg mice following injection with LNA-an-
timiR-214 (Fig. 6d). In clinical samples, there was a significant
negative correlation between the expression of miR-214 and
Mig-6 in the liver of patients with chronic hepatitis C
(Figs S1a and S5a).
The functional role of miR-214 in EGFR signaling was ana-
lyzed in two human HCC cell lines (Huh-7 and HLF) in which
the basal expression level of miR-214 was low and high,
respectively (Fig. 1a). The MTS assay showed a significant
increase in the number of Huh-7 cells following stimulation
with EGF or miR-214 overexpression (Fig. 7a). EGF further
augmented the proliferation of Huh-7 cells in which miR-214
was overexpressed. Mimic-miR-214 decreased the expression
of Mig-6 and increased the levels of EGF-mediated p-EGFR
(Y1173 and Y845) and p-Met (Tyr1234 ⁄ 1235; Fig. 7b). When
the expression of Mig-6 was repressed using two different
(a) (b)
Fig. 4. Quantitative evaluation of the expression of pro-fibrotic genes using TaqMan real-time detection-PCR (RTD-PCR) and western blotting.
(a) Quantitative analysis of the expression of pro-fibrotic genes using TaqMan RTD-PCR. Fibrotic areas in mouse liver were measured semi-quanti-
tatively by densitometry analysis (n = 6 each). (b) Western blotting analysis of the expression of pro-fibrotic genes (a-SMA, ERK 1 ⁄ 2, p-ERK 1 ⁄ 2,
AKT and p-AKT) and protein synthesis (S6K and p-S6K).
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
Cancer Sci | September 2015 | vol. 106 | no. 9 | 1148
Original Article
AntimiR-214 improves hepatic fibrosis and HCC www.wileyonlinelibrary.com/journal/cas
siRNA (siMig-6-1 and siMig-6-2), the growth of Huh-7 cells
was significantly increased (Fig. 7c) and the levels of EGF-
mediated p-EGFR (Y1173 and Y845) and p-Met (Tyr1234
⁄1235) were substantially increased (Fig. 7d). Conversely,
when the expression of miR-214 was repressed in HLF cells
by LNA-antimiR-214, their proliferation was significantly
repressed (Fig. 7e) and the levels of EGF-mediated p-EGFR
(Y1173 and Y845) and p-Met (Tyr1234 ⁄1235) were substan-
tially decreased (Fig. 7f). The combination of LNA-antimiR-
214 and siMig-6 (siMig-6-1 and siMig-6-2) partially, but not
significantly, rescued the growth of HLF cells (Fig. S5b).
Discussion
Micro RNA are small regulatory RNA that play important
roles in developmental processes and various diseases, includ-
ing infection and cancer, and could, therefore, be potential tar-
gets for therapeutic intervention. The therapeutic use of the
repression of specific miRNA using LNA-modified DNA phos-
phorothioate antisense oligonucleotides has been applied suc-
cessfully to liver-expressed miR-122 in humans. This approach
could be applicable to hepatic fibrosis induced by various
etiologies.(15)
In this study, we focused on miR-214, which was the most
significantly upregulated miRNA in the liver of Pdgf-c Tg mice.
Moreover, we showed that the expression of miR-214 was
upregulated with the progression of hepatic fibrosis in a diet-in-
duced (Ath + HF) NASH mouse model(11) and in patients with
chronic hepatitis B or C (Fig. S1a,b). The upregulation of miR-
214 was reported in a methionine choline-deficient diet mouse
model(16) and a dimethylnitrosamine-induced hepatic fibrosis rat
model.(17) However, others reported the downregulation of miR-
214 in toxin-induced liver injury that was induced by ethanol
feeding(16) and exposure to CCl4 and thioacetamide.(18) The pre-
cise mechanism of the differential regulation of miR-214 has
not been characterized; however, miR-214 was reportedly
upregulated in old mice and was related to decreased liver func-
tion, such as alcohol metabolism and glutathione metabolism.(19)
Further studies should be performed to reveal the differential
regulation of miR-214 in different liver fibrosis models.
Interestingly, we found that many hepatocytes and HCC-
derived cells (THTL-5b, TTNT, Huh-7, Huh-1, HepG2 and
Hep3B) expressed low levels of miR-214, while some HCC
cells (HLE and HLF) expressed abundant levels. Recently, we
reported that there are two cancer stem cell marker-positive
cell types (EpCAM+ or CD90+) in HCC cell lines and the
(a) (c)
(b)
Fig. 5. Repeated injection of locked nucleic acid (LNA)-antimiR-214 and tumor incidence in Pdgf-c Tg mice. (a) Pdgf-c Tg or WT mice at
32 weeks of age were injected repeatedly with LNA-antimiR-214, LNA-antimiR-control or saline via the tail vein for a total of six times. One week
after the final injection, the mice (each group = 6) were killed. (b) Gross appearance of livers from Pdgf-c Tg or WT mice injected repeatedly
with LNA-antimiR-214, LNA-antimiR-control or saline (n = 6). (c) Evaluation of fibrosis, tumors, albumin (mRNA) and serum AST in the liver of
Pdgf-c Tg mice injected repeatedly with LNA-antimiR-214, LNA-antimiR-control, or saline (n = 6).
Cancer Sci | September 2015 | vol. 106 | no. 9 | 1149 © 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
Original Article
www.wileyonlinelibrary.com/journal/cas Okada et al.
gene expression profiles and characteristics of these cells are
different. EpCAM+ cells (Huh-7, Huh-1, HepG2 and Hep3B)
have a polygonal and epithelial cell shape, while CD90+ cells
(HLE and HLF) have a spindle cell shape. EpCAM+ cells
express genes with a known function in hepatocytes, while
CD90+ cells express endothelial and mesenchymal markers
and possess high metastatic capacity.(20) Therefore, these find-
ings supported the present result that miR-214 was mainly
expressed in mesenchymal cells.
In the present study, we showed the possibility of a unique
induction system of miR-214 in hepatocytes. We hypothesize
that miR-214 is transferred to hepatocytes by exosomes released
from surrounding mesenchymal cells with the progression of
hepatic fibrosis. We found that co-culture of Huh-7 cells with
Lx-2 cells significantly increased the intracellular levels of
miR-214 in Huh-7 cells. Furthermore, by the addition of med-
ium or exosomes derived from Lx-2 cells to the culture medium
of Huh-7 cells, we showed the significant increase in intracellu-
lar miR-214 levels in Huh-7 cells (Fig. 1d). Interestingly, gene
expression analysis and a spheroid formation assay showed that
Huh-7 cells acquired a more malignant tumor cell phenotype
when co-cultured with Lx-2 cells. These results demonstrate
that miR-214 is transferred to hepatocytes by exosomes, which
are released from activated stellate cells and increased miR-214
levels might play a role in the transformation of hepatocytes. A
recent report showed that endothelial cells release miR-214-
containing exosomes to stimulate angiogenesis through the
silencing of ataxia telangiectasia mutated in neighboring target
cells.(21) It could be speculated that this unique miRNA distribu-
tion system would be beneficial for the long-lasting efficacy of
miRNA as they are protected from degradation processes. How-
ever, as exosomes contain unknown mRNA and proteins, it
should be noted that such unknown factors could upregulate the
levels of intrinsic miR-214.
Several reports showed that the expression of miR-214 was
upregulated in activated HSC;(22,23) however, one report
described the downregulation of miR-214.(18) Our study
showed the upregulation of miR-214 in activated HSC
(Fig. 1a,b). TGF-b1 stimulated the expression of miR-214 in
Lx-2 cells (Fig. 1c). Moreover, repression of miR-214 in Lx-2
cells significantly decreased the expression of pro-fibrotic
genes (collagen 1a2 and 4a1), EMT-related genes, and TGF-b1






Fig. 6. MiR-214 targets the EGFR signaling inhibitor Mig-6. (a) Sequence alignment of putative binding sites of miR-214 in the 30-UTR sequence
of Mig-6 and the construction of the reporter plasmid (pmirGLO-Mig-6). (b) Locked nucleic acid (LNA)-antimiR-214 significantly increased the
luciferase activity of pmirGLO-Mig-6, a reporter plasmid containing the putative binding site of miR-214 in the 30-UTR of Mig-6, while mimic-214
decreased the luciferase activity of pmirGLO-Sema6A (n = 6). (c) Changes in the expression of Mig-6 in the liver of Pdgf-c Tg mice that were
injected with saline, LNA-antimiR-control or LNA-antimiR-214 (n = 5). (d) Western blotting of EGFR-related genes in the liver of Pdgf-c Tg mice
that were injected with saline, LNA-antimiR-control or LNA-antimiR-214. All experiments were performed in duplicate and repeated three times.
*P < 0.05, **P < 0.01, ***P < 0.001, Values are means  SD.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
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To evaluate the therapeutic potential of the repression of
miR-214 for anti-fibrosis in vivo, LNA-antimiR-214 was deliv-
ered efficiently into the liver using Invivofectamine 2.0 (Fig. 3).
We observed the colocalization of FAM-labeled LNA-antimiR-
214 and a-SMA-, desmin-, F4 ⁄ 80- and AFP-positive cells
stained using an APC-labeled antibody. These results suggested
that LNA-antimiR-214 could be introduced into stellate cells,
macrophages and hepatocytes (data not shown). LNA-antimiR-
214 efficiently improved hepatic fibrosis in young (9 weeks
old) and old (48 weeks old) mice (Figs 2c and S4a). We
observed a significant reduction in the mRNA levels of pro-fi-
brotic genes, such as collagen 1a2, collagen 4a1, TGF-b1 and
a-SMA, which was associated with decreased levels of p-ERK1
⁄2 and p-AKT (Fig. 4). No obvious histological changes were
observed in the lung, heart, kidney and spleen following six
injections of LNA-antimiR-214. To our knowledge, this is the
first report to demonstrate that LNA-antimiR treatment could
prevent the progression of hepatic fibrosis in an in vivo mouse
model. A recent report showed that genetic deletion of miR-214
significantly attenuated kidney interstitial fibrosis induced by
unilateral ureteral obstruction.(24)
Interestingly, the repeated injection of LNA-antimiR-214
into Pdgf-c Tg mice significantly reduced tumor number and
volume (Fig. 5). The anti-tumor effect of LNA-antimiR-214
might be due to a secondary effect by reducing the fibrotic
state or inflammation of the liver. A recent report showed that
pharmacological inhibition of EGFR signaling by erlotinib
effectively prevented the progression of hepatic fibrosis and
blocked the development of HCC.(25)
We also found that Mig-6, an inhibitor of EGFR, is a putative
target of miR-214 (Fig. 6). Mig-6 inhibits EGFR catalytic activ-
ity by interfering with its dimerization.(14) The expression of
Mig-6 was repressed in Pdgf-c Tg mice and recovered by LNA-
antimiR-214 (Fig. 6c,d), which was consistent with the
increased EGFR signaling by mimic-miR-214 and decreased
EGFR signaling by LNA-antimiR-214 in cells (Fig. 7b,f). Mig-
6 could be a target of miR-214 in Lx-2 cells as well as in hepa-
tocytes. Repression of miR-214 by LNA-antimiR-214 increased
Mig-6 levels significantly and overexpression of Mig-6 signifi-
cantly repressed the expression of collagen 1a2, collagen 4a1,
PDGFRb and N-cadherin in Lx-2 cells (Fig. S5c). Moreover,
overexpression of Mig-6 repressed the levels of p-AKT (473),
p-AKT (308) and p-ERK in Lx-2 cells (Fig. S5d). Thus, our
results demonstrate that miR-214 is a pro-fibrotic miRNA by
regulating TGF-b and EGFR signaling, and LNA-antimiR-214
resolves hepatic fibrosis in vitro and in vivo.
In addition to pro-fibrotic signaling, LNA-antimiR-214 sub-
stantially increased the levels of many ribosomal proteins
(Fig. S2), including ribosomal protein S5 (RPS5; data not
shown). A recent report showed that overexpression of RPS5
alleviated the progression of dimethylnitrosamine-induced and
bile duct ligation-induced hepatic fibrosis.(26) Moreover, the
upregulation of ribosomal proteins by LNA-antimiR-214 might
explain the improved protein synthesis and liver function, as
demonstrated by the increased serum levels of albumin (Fig. 5).
MiR-214 is involved in hedgehog signaling and targets the
phosphatase and tensin homolog(27) and p53,(28) and its expres-
sion is upregulated in ovarian, stomach, pancreatic, cervical,
lung and oral mucosal cancers, and malignant melano-
mas.(27,29) Conversely, the decreased expression of miR-214 in
HCC has been reported, and it might be related to reduced dis-
ease-free survival by upregulating the expression of hepatoma-
(a) (c) (e)
(b) (d) (f)
Fig. 7. Mir-214 regulates tumor cell growth through EGFR signaling in Huh-7 and HLF cells. (a) Huh-7 cells were grown in 96-well plates under
serum-free condition with ⁄ without recombinant EGF. Huh-7 cells were transfected with mimic-miR-214 at 24 h prior to the proliferation assay.
After 48 h of culture, cell number was assessed by the MTS assay (n = 6). (b) Western blotting of Mig-6, p-EGFR, and p-MET in Huh-7 cells in
which miR-214 was over-expressed with ⁄ without recombinant EGF. (c) Cell proliferation assay of Huh-7 cells in which Mig-6 was repressed using
two different siRNA to Mig-6 (n = 6). (d) Western blotting of Mig-6, p-EGFR, and p-MET in Huh-7 cells in which Mig-6 was repressed with ⁄ with-
out recombinant EGF. (e) HLF cells were grown in 96-well plates under serum-free conditions with ⁄ without recombinant EGF. HLF cells were
transfected with LNA-antimiR-214 at 24 h prior to the proliferation assay. After 48 h of culture, cell number was assessed by the MTS assay
(n = 6). (f) Western blotting of Mig-6, p-EGFR and p-MET in Huh-7 cells in which miR-214 was repressed with ⁄ without recombinant EGF.
*P < 0.05, **P < 0.01, ***P < 0.001, All experiments were performed in duplicate and repeated three times. Values are means  SD.
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derived growth factor.(30) Although our model showed that
reduced miR-214 levels improved hepatic fibrosis and reduced
the incidence of hepatic tumors, the functional relevance of
miR-214 in tumor cells should be explored further.
In summary, we demonstrated that LNA-antimiR-214 treat-
ment could prevent the progression of hepatic fibrosis in an
in vivo mouse model for the first time. Further study should be
performed to assess the clinical application of LNA-antimiR-
214 for hepatic fibrosis.
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